Motif Plunges As FDA Demands New Iclaprim Study

The UK biotech is in dire need of further funding after US regulators requested an additional clinical trial for its much-delayed skin infection antibiotic.

Sea
Storm clouds over Motif Bio • Source: Shutterstock

Motif Bio PLC has been dealt a serious blow from the US Food and Drug Administration which has told the cash-strapped UK biotech it needs to carry out an additional trial for iclaprim if it wants any hope of getting approval for the antibiotic.

The company has been on unsteady ground ever since February when the FDA issued a complete response letter for iclaprim,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas